← Human Trials & Peer-Reviewed Studies
Association between dynamic exercise therapy and IGF-1 and IGFBP-3 concentrations in the patients with rheumatoid arthritis
Plain-language guide to PMID 15933856 (2006): randomized controlled trial study of IGF-1 LR3 in 3 participants, rheumatoid arthritis.
Key Facts
- PMID
- 15933856
- Journal
- Rheumatology international
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Melikoglu MA et al. (4 authors)
- DOI
- 10.1007/s00296-005-0605-y
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at IGF-1 LR3 in the context of rheumatoid arthritis.
The researchers aimed to evaluate the relationship between short-term dynamic exercise therapy and insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) levels in rheumatoid arthritis (RA) patients.
Why It Was Studied
Also control group carried out the same dynamic exercise protocol.
The assessments were determined before, at the 7th and 15th days of treatment.
Who Took Part
According to the abstract, 3 participants were involved.
By PubMed's age tags, the people studied were adults and middle-aged adults, women only.
Forty RA patients were assigned into dynamic or range of motion (ROM) exercise groups.
Morning stiffness, pain (VAS), Health assessment questionnaire (HAQ) and Ritchie articular index (RAI) were evaluated and erythrocyte sedimentation rate, serum C-reactive protein, IGF-1 and IGFBP-3 levels of the participants were recorded.
How the Study Was Run
The design is described as randomized.
The participants were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.
What Was Measured
The assessments were determined before, at the 7th and 15th days of treatment.
PubMed files the paper under topics including Arthritis, Rheumatoid, Exercise Therapy, Health Status, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Range of Motion, Articular and Surveys and Questionnaires.
What This Means in Plain Language
The paper is a randomized study of IGF-1 LR3 in 3 participants in people with rheumatoid arthritis.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2006 (Rheumatology international), a journal based in Germany.
More context: the IGF-1 LR3 compound page, Rheumatoid arthritis research.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.